Headache management for the pain specialist

Ashkenazi, Avi; Silberstein, Stephen D.

doi:10.1097/00115550-200409000-00012

Cited by 12 publications

(9 citation statements)

References 61 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3,4 Anesthetic block of the cervical structures or their nerve supply has been recommended to support the diagnosis of CGH. 1,4 A small number of studies support the efficacy of peripheral nerve blocks for treatment of CGH. 1 As a subset of CGH, occipital neuralgia can involve the posterior scalp, the periorbital, temporal, and mandibular regions, the external ear and mastoid region, and the neck and shoulder.…”

Section: Discussionmentioning

confidence: 99%

“…1,4 A small number of studies support the efficacy of peripheral nerve blocks for treatment of CGH. 1 As a subset of CGH, occipital neuralgia can involve the posterior scalp, the periorbital, temporal, and mandibular regions, the external ear and mastoid region, and the neck and shoulder. Various disorders should be considered as possible causes of occipital pain syndrome (Table 1).…”

Section: Discussionmentioning

confidence: 99%

“…9,12 The value of nerve blocks in the differential diagnosis and effective treatment of such headaches has been suggested. 1,13,18 The following cases that occurred within a 4-month timeframe illustrate that this differential is a valid diagnostic challenge with significant clinical implications.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Cervicogenic Headache in Patients With Presumed Migraine: Missed Diagnosis or Misdiagnosis?

Cook

Hamill-Ruth

et al. 2005

The Journal of Pain

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cervicogenic Headache in Patients With Presumed Migraine: Missed Diagnosis or Misdiagnosis?

Cook

Hamill-Ruth

et al. 2005

The Journal of Pain

View full text Add to dashboard Cite

“…117 There is still lack of controlled trials to support its use as a first line agent. [118][119][120][121][122][123] Creating a "miracle drug" to relieve any sort of pain is irrational due to the molecular complexity pain neurobiology presents. Smarter centrally acting medications are needed.…”

Section: Requirement For Smarter Medications-mentioning

confidence: 99%

Is There Hope for Chronic Pain and Headache?

Graff‐Radford¹

2007

Headache

View full text Add to dashboard Cite

Currently the clinical needs for pain and headache management are not met. Despite the numerous and exciting recent advances in understanding the molecular and cellular mechanisms that originate pain, we cannot yet fully explain the mechanism underlying the biology of chronic pain. Pain is a natural mechanism preserving our species survival; however, when the protective quality is lost, physiologic changes to the peripheral and central nervous systems result in the formation of chronic pain states. Once we understand how this chronic pain state is created, either through genetic, environmental, therapeutic, or other triggers we may be able to enhance our species existence, limiting maladaptive pain and suffering. The future therapeutic targets will need to address the genetics, neurophysiologic changes of the neurons and brain as well as help control immune systems including the glia. The key to successful headache and pain therapy is research aimed at prevention and minimizing the plastic changes triggering chronic pain.

show abstract

“…Kronik GTBA'nın yıllık prevalansı %2-3 oranında bildirilmesine rağmen toplumun daha büyük kısmını etkilediği düşünülmektedir. [4] Türkiye baş ağrısı epidemiyoloji verilerine göre Türkiye'de GTBA prevalans oranları epizodik GTBA için %20-%30, kronik GTBA için %3.1 olarak bulunmuştur. [5] GTBA prevalansı en sık 2. ve 5. dekatlarda görülmektedir.…”

Section: Introductionunclassified